RE:We need to find out more about the 18% mortality benefitI fully agree. This number is quite significant and could be pointing toward a possible FDA approval for some specific subgroup and/or indication. There is to much panicking right now with a lot of speculations and guessing. We need a conference call and/or a very detailed letter or presentation to shareholders. I see a lot of positive in this morning PR despite the trial not meeting its primary end points.